The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
The Risk of Cancer in Users of Statins
Open accessAbstract
Purpose: Several preclinical studies suggested a role for 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) in the treatment of cancer. The objective of this study was to compare the risk of incident cancer between users of statins and users of other cardiovascular medication. Methods: Data were used from the PHARMO database, containing drug dispensing records from community pharmacies and linked hospital discharge records for residents of eight Dutch cities. The study base included all patients with one or more prescriptions for cardiovascular drugs in the period between January 1, 1985 and December 31, 1998. Cases were identified as patients in the study base with a diagnosis of incident cancer and matched with four to six controls on sex, year of birth, geographic region, duration of follow-up, and index date. The analysis was adjusted for diabetes mellitus; prior hospitalizations; comorbidity; and use of diuretics, angiotensin-converting enzyme inhibitors, calcium-channel blockers, nonsteroidal anti-inflammatory drugs, sex hormones, and other lipid-lowering drug therapies. Results: In the study base, 3,129 patients were identified and matched to 16,976 controls. Statin use was associated with a risk reduction of cancer of 20% (adjusted odds ratio [OR], 0.80; 95% CI, 0.66 to 0.96). Our data suggest that statins are protective when used longer than 4 years (adjusted OR, 0.64; 95% CI, 0.44 to 0.93) or when more than 1,350 defined daily doses are taken (adjusted OR, 0.60; 95% CI, 0.40 to 0.91). Conclusion: This observational study suggests that statins may have a protective effect against cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
Regulation of the mevalonate pathway
Goldstein, J. L., & Brown, M. S. (1990) · Nature · doi:10.1038/343425a0 · Cited by 5,394
(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
Downs, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., Langendorfer, A., Stein, E. A., Kruyer, W., Gotto, Jr., et al. (1998) · JAMA · doi:10.1001/jama.279.20.1615 · Cited by 5,236
ras oncogenes in human cancer: a review.
Bos, J. L. (1989) · PubMed · Cited by 5,061
PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA
Hepherd, J. A. S., Obbe, S. T. M. C., Ord, I. A. F., Sles, C. H. G. I., Orimer, A. R. O. L., Acfarlane, P. E. W. M., Illop, J. A. H. M. C. K., Ackard, C. H. J. P., & Roup, S. T. G. (1995) · Cited by 3,453
Statins and the risk of dementia
Jick, H., Zornberg, G., Jick, S., Seshadri, S., & Drachman, D. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03155-x · Cited by 1,759
Wolozin, B. (2000) · Archives of Neurology · doi:10.1001/archneur.57.10.1439 · Cited by 1,398
A chronic disease score from automated pharmacy data
Von Korff, M., Wagner, E. H., & Saunders, K. (1992) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(92)90016-g · Cited by 961
Blocking Oncogenic Ras Signaling for Cancer Therapy
Adjei, A. A. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.14.1062 · Cited by 831
Carcinogenicity of Lipid-Lowering Drugs
Newman, T. B. (1996) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1996.03530250059028 · Cited by 380
Validation of pharmacy records in drug exposure assessment
Lau, H. S., de Boer, A., Beuning, K. S., & Porsius, A. (1997) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(97)00040-1 · Cited by 370
Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer.
Thibault, A., Samid, D., Tompkins, A. C., Figg, W. D., Cooper, M. R., Hohl, R. J., Trepel, J. B., Liang, B., Patronas, N., Venzon, D. J., et al. (1996) · PubMed · Cited by 362
Kawata, S., Yamasaki, E., Nagase, T., Inui, Y., Ito, N., Matsuda, Y., Inada, M., Tamura, S., Noda, S., Imai, Y., et al. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2000.1716 · Cited by 354
Blais, L., Desgagné, A., & LeLorier, J. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.15.2363 · Cited by 326
Pedersen, T. R., Wilhelmsen, L., Færgeman, O., Strandberg, T. E., Thorgeirsson, G., Troedsson, L., Kristianson, J., Berg, K., Cook, T. J., Haghfelt, T., et al. (2000) · The American Journal of Cardiology · doi:10.1016/s0002-9149(00)00910-3 · Cited by 274
Cholesterol and Alzheimer’s disease: Is there a link?
Simons, M., Keller, P., Dichgans, J., & Schulz, J. B. (2001) · Neurology · doi:10.1212/wnl.57.6.1089 · Cited by 257
Dimitroulakos, J., Nohynek, D., Backway, K. L., Hedley, D. W., Yeger, H., Freedman, M. H., Minden, M. D., & Penn, L. Z. (1999) · Blood · doi:10.1182/blood.v93.4.1308 · Cited by 219
Nègre-Aminou, P., van Vliet, A. K., van Erck, M., van Thiel, G. C. F., van Leeuwen, R. E. W., & Cohen, L. H. (1997) · Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism · doi:10.1016/s0005-2760(96)00184-1 · Cited by 212
Do statins cause cancer? A meta-analysis of large randomized clinical trials
Bjerre, L. M., & LeLorier, J. (2001) · The American Journal of Medicine · doi:10.1016/s0002-9343(01)00705-7 · Cited by 195
Dimitroulakos, J., Ye, L. Y., Benzaquen, M., Moore, M. J., Kamel‐Reid, S., Freedman, M. H., Yeger, H., & Penn, L. Z. (2001) · PubMed · Cited by 164
Alonso, D. F., Fariña, H. G., Skilton, G., Gabri, M. R., Lorenzo, M. S. D., & Gomez, D. E. (1998) · Breast Cancer Research and Treatment · doi:10.1023/a:1006058409974 · Cited by 146
Hadfield, G., & GARROD, L. P. (1934) · BMJ · doi:10.1136/bmj.1.3831.1049-a · Cited by 116
Inhibition of pancreatic adenocarcinoma cell growth by lovastatin
Sumi, S., Beauchamp, R. D., Townsend, C. M., Uchida, T., Murakami, M., Rajaraman, S., Ishizuka, J., & Thompson, J. C. (1992) · Gastroenterology · doi:10.1016/0016-5085(92)90032-t · Cited by 107
Lovastatin Induces Apoptosis in Malignant Mesothelioma Cells
Rubins, J. B., Greatens, T. M., Kratzke, R. A., Tan, A., Polunovsky, V. A., & Bitterman, P. B. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.157.5.9709020 · Cited by 102
Lovastatin-induced Apoptosis of Human Medulloblastoma Cell Lines in vitro
Macaulay, R. J. B., Wang, W., Dimitroulakos, J., Becker, L. E., & Yeger, H. (1999) · Journal of Neuro-Oncology · doi:10.1023/a:1006164406202 · Cited by 78
Kawata, S., Nagase, T., Yamasaki, E., Ishiguro, H., & Matsuzawa, Y. (1994) · British Journal of Cancer · doi:10.1038/bjc.1994.199 · Cited by 64
Increased sensitivity of multidrug-resistant myeloid leukemia cell lines to lovastatin
Maksumova, L., Ohnishi, K., Muratkhodjaev, F., Zhang, W., Pan, L., Takeshita, A., & Ohno, R. (2000) · Leukemia · doi:10.1038/sj.leu.2401856 · Cited by 37
Apoptosis of medulloblastoma cellsIn vitro follows inhibition of farnesylation using manumycin A
Wang, W., & Macaulay, R. J. B. (1999) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19990730)82:3<430::aid-ijc17>3.0.co;2-9 · Cited by 36
Hydroxymethylglutaryl-Coenzyme A Reductase Inhibitors in Osteoporosis Management
Coons, J. C. (2002) · Annals of Pharmacotherapy · doi:10.1345/aph.1a071 · Cited by 22
Cited by
Interpretation of the evidence for the efficacy and safety of statin therapy
Collins, R., Reith, C., Emberson, J., Armitage, J., Baigent, C., Blackwell, L., Blumenthal, R., Danesh, J., Smith, G. D., DeMets, D., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31357-5 · Cited by 1,857
Demierre, M.-F., Higgins, P. D. R., Gruber, S. B., Hawk, E., & Lippman, S. M. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1751 · Cited by 819
Statins and the Risk of Colorectal Cancer
Poynter, J. N., Gruber, S. B., Higgins, P. D. R., Almog, R., Bonner, J. D., Rennert, H. S., Low, M., Greenson, J. K., & Rennert, G. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043792 · Cited by 816
Mevalonate pathway: A review of clinical and therapeutical implications
Buhaescu, I., & Izzedine, H. (2007) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2007.03.016 · Cited by 620
Statins and Cancer Risk: A Meta-analysis
Dale, K. M., Coleman, C. I., Henyan, N. N., Kluger, J., & White, C. M. (2006) · JAMA · doi:10.1001/jama.295.1.74 · Cited by 599
Metadata
- Authors
- Graaf, M. R., Beiderbeck, A. B., Egberts, A. C. G., Richel, D. J., & Guchelaar, H.-J.
- Venue
- Journal of Clinical Oncology
- Published
- 2004-06-15
- Volume
- 22
- Issue
- 12
- Pages
- 2388-2394
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2129732555
- Cited by
- 528
- References
- 31
- FWCI
- 15.43
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.